形态:Liquid
纯度:>95% as determined by SDS-PAGE.
内毒素水平:Please contact with the lab for this information.
应用:ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属:Human
表达系统:Mammalian Cells
登录号:P02778
宿主种属:Human
克隆性:Monoclonal
抗体亚型:IgG1-kappa
纯化方式:Protein A/G purified from cell culture supernatant.
浓度:1 mg/ml
种属反应性:Human
靶标:Gamma-IP10, C-X-C motif chemokine 10, INP10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, SCYB10, IP-10, CXCL10
储存缓冲液:0.01M PBS, pH 7.4.
稳定性和储存:Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
背景信息:Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.<br>• The human gene encoding SCYB9B, a putative novel CXC chemokine, maps to human chromosome 4q21 like the closely related genes for MIG (SCYB9) and INP10 (SCYB10)., PMID:9730616<br/>
别名:BMS-936557, MDX-1100, 946414-98-8
备注:For research use only. Not suitable for clinical or therapeutic use.